Health Kick Podcast: Imagion Biosystems
In this episode, Tim speaks with Imagion Biosystems (ASX:IBX) chairman Robert Proulx and company advisor Dr Leonardo Kayat Bittencourt.
Did you know that X-ray technology was invented more than a century ago? You can thank German scientist Wilhelm Conrad Röntgen for that.
Since then, diagnostic technology in the healthcare sector has made leaps and bounds, and one of the companies at the forefront is Imagion Biosystems.
Tune in to hear how IBX is accelerating early detection of cancer, how their MagSense Technology works, and more.
This podcast was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
6 minutes ago
- ABC News
More grievances against prosthetic eye maker Jack McDonald's work
Ron Clark lost an eye after developing a severe infection. "The eye sort of melted, and they had to do emergency surgery to remove it," he said. As a consultant who spends much of his time doing business face-to-face, Mr Clark was eager to have an artificial eye made. But he was very unhappy with the eye made for him by ocularist Jack McDonald, which he said "bulged out of the socket". He said the situation became "intolerable" after the eye fell out while he was at dinner. "It was quite undesirable and confronting — a bit embarrassing frankly," he said. Mr Clark decided to speak out after other clients of Mr McDonald shared their experiences with the ABC. "I don't want anybody else to suffer through like I have," he said. Mr McDonald is described on his website as a trained ocularist and maxillofacial (face and jaw) prosthetist providing "ultra-realistic and world-class prostheses". His website states his services include prosthetic eyes, ears, fingers and noses. Previously, his website stated Mr McDonald was operating out of offices in Sydney, Melbourne, Dandenong, Hobart, Adelaide, Brisbane, Perth, Geelong and Auckland. Now, his website no longer lists the locations he works from, but there are contact numbers for Sydney and Melbourne offices. Fifteen people contacted the ABC with similar stories of disappointment and dissatisfaction with Mr McDonald's work after the initial story about him was published. "It's something that brings out a lot of emotion in me because it's a very confronting experience," Mr Clark said. Do you know more? Contact Fiona Blackwood at Mr Clark said his experience with Mr McDonald was characterised by "multiple visits, multiple cancellations, multiple attempts at creating the eye, followed by a failure to succeed". Mr Clark lost faith in the process and has since had an eye made with a different ocularist, which he is very satisfied with. The president of the Ocularists Association of Australia, Peter Knowles, who has more than 35 years of experience, took a look at the eye Mr McDonald made for Mr Clark. He described it as unsightly and "bulging, its gaze is upward, its colour doesn't match". "It's loading the lower eyelid in a manner that could cause damage and therefore [could] need surgical construction," Mr Knowles said. Mr Knowles said he also received phone calls from unhappy clients of Mr McDonald after the ABC story was published. Mr Knowles is concerned Mr McDonald is continuing to see patients. Liana* lost her eye to melanoma when she was just 29. She initially saw Jack McDonald for an unrelated matter last year, and he promised he could make her a better artificial eye than the one she already had. With high hopes, Liana paid $2,800 up front for the eye at her first appointment in August last year. She said she attended 11 appointments, but Mr McDonald struggled to get the eye right. "The prosthetic he created looked unnatural and was the wrong size; it protruded so far that it was unsettling to look at," she said. Liana said she also received frequent text messages from Mr McDonald's office cancelling or rescheduling appointments. "On the last occasion, when they blamed flight delays from Hobart, I checked all carriers and found no cancellations or delays that day," she said. She twice asked Mr McDonald for a refund, but was refused. In the end, she provided evidence to her bank demonstrating that she had not received an acceptable eye and the bank agreed to reverse the $2,800 credit card payment to Mr McDonald. Liana's experience has come at a personal cost. "My experience with Jack was traumatic, losing my eye to cancer in 2019 was one of the hardest years of my life, and Jack reopened many of those emotional wounds while making me feel even more insecure," she said. She is calling for regulation of the industry. "There needs to be someone there to say: 'Your work is not up to standard, you can't be operating,'" she said. There are no government regulatory hurdles to clear before being able to act as an ocularist in Australia and no requirement to be a member of an Ocularist Association. Mr McDonald is not a member of the Ocularist Association of Australia, nor is he required to be. He has not responded to the ABC's request for comment. Wayne Dryden described his year-long wait for Jack McDonald to make him a suitable eye as "one of the worst experiences" of his life. He said after 21 appointments, he has given up hope Mr McDonald will ever make him a wearable artificial eye. Those so far have been the wrong colour, ill-fitting and painful, he said. "Absolutely terrible and very disheartening," Mr Dryden said. Mr Dryden took out a bank loan to pay $2,800 for the eye. With travel costs associated with his many appointments, he said his efforts for a suitable prosthetic have "roughly cost me $6,000 within the 12 months". He said he pursued a refund, but Mr McDonald refused. Mr Dryden is having to make do with a scratched artificial eye, which he has had for more than 30 years — as he can't afford to see another ocularist. He said he wants to take legal action against Mr McDonald, but can't afford that either. "He needs to be accountable for what he's done to people, not only myself, other people." Ocularist Peter Knowles has encouraged unsatisfied clients of Jack McDonald to go to their state's Health Complaints Commission. But he is concerned that many clients with grievances, like Mr Dryden, are out of pocket. He said while some clients can't afford legal fees, clients could consider a class action. Mr Knowles said people who have lost an eye through trauma, birth deformity or disease are vulnerable, and there "should be a mechanism whereby a person can be made accountable". 'There is no such thing as pleasant eye loss … and so to give them back an eye is to give them back their connection with people," he said. The unregulated nature of the industry means avenues for help or refunds are unclear, according to the Health Consumers Commission. "The health complaints space is a very busy and sometimes very messy area to navigate as a community member," chief executive Dr Elizabeth Deveny said. The Health Consumers Commission is calling on the federal government to bring the sector together with clients and clinicians to talk about how best to improve the situation. "These devices affect people's lives in their function, their dignity, their ability to do things. "It's terrible to hear that people have had a very poor experience." *Name has been changed for privacy.
The Australian
an hour ago
- The Australian
Imagion raises $3.5m to advance early cancer detection clinical program
Imagion secures $3.5 million in capital raise to sophisticated investors and family offices Placement to support ongoing clinical program for MagSense Imaging agent for cancer Company currently preparing to undertake Phase II trial in HER2+ breast cancer in the US Special Report: Imagion Biosystems has raised $3.5 million through a heavily oversubscribed two-tranche placement to sophisticated investors and family offices as it prepares to launch a Phase II trial of its MagSense imaging technology for HER2+ breast cancer in the US. The placement, led by CPS Capital, was priced at 1.5 cents per share with one free attaching listed option exercisable at 4 cents and expiring on December 13, 2027. The offer price represented a 10% discount to the 10-day volume-weighted average price (VWAP) for Imagion Biosystems (ASX:IBX) shares before announcement of the capital raising. Directors will also contribute $150,000 based on the same terms and conditions, subject to shareholder approval at an extraordinary general meeting in September. The placement consists of two tranches including: Tranche 1 –45 million new shares to raise ~$675,000 with settlement on August 5 and allotment of new shares on August 6 Tranche 2 – The balance of shares (~$2.8m) conditional on shareholder approval at an EGM The EGM is scheduled for September 18 with settlement of tranche 2 earmarked for September 19. Allotment of new shares under tranche 2 and new listed options under both tranches is set for September 22. Listen to more from IBX: Imagion's cancer imaging alternative Use of proceeds to advance clinical program Funds will be used to advance Imagion's MagSense imaging technology, specifically for HER2 breast cancer and initiate the Phase I clinical programs for both prostate and ovarian cancer. Imagion's trademarked platform aims to revolutionise cancer diagnosis by introducing molecular imaging to MRI. The company expects to initiate its HER2 breast cancer trial in the near term with key objectives for the company including: Submission of an investigational new drug (IND) application to the US Food and Drug Administration (FDA) Completion of drug manufacturing to support the trial Filing of new intellectual property (IP) applications related to molecular MRI Initiation of the trial and completion of first patient cohort Collaborations with MRI experts to develop a quantitative MRI platform and AI-based modelling optimised for MagSense 'We are very pleased with the strong demand we saw from investors following our recently announced progress with the FDA on the IND submission for our upcoming HER2+ Breast Cancer Phase 2 clinical trial,' IBX executive chairman Robert Proulx said. 'I want to thank CPS Capital for their lead role and all the investors who have shown their support for our clinical plan.' This article was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Sponsored Nova Minerals has released a conceptual processing flowsheet for its 1.24Moz RPM deposit in Alaska. Sponsored Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease.
The Australian
2 hours ago
- The Australian
Break it Down: Heavy Rare Earths primed for Prospect Hill tin perforation
Stockhead's Break it Down brings you today's leading market news in under 90 seconds. In this episode, host Tylah Tully looks at news from Heavy Rare Earths (ASX:HRE), who have entered a new deal with major shareholder Havilah Resources (ASX:HAV) and secured the rights to all minerals at Prospect Hill - South Australia's most advanced and largest known tin project. Watch the video to learn more. While Heavy Rare Earths is a Stockhead advertiser, it did not sponsor this content. Sponsored Nova Minerals has released a conceptual processing flowsheet for its 1.24Moz RPM deposit in Alaska. Sponsored Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease.
